Eli Lilly Reports 39% Q3 Revenue Growth, Raises 2026 Sales Outlook And Advances Drug Pipeline

Eli Lilly (LLY) reported Q3 2026 revenue growth of 39% to $24.397B, driven by Mounjaro and Zepbound. Net income rose to $6.451B. The company raised its full-year revenue outlook to $91B-$92B but lowered adjusted EPS guidance to $35.00-$36.00 due to acquisition-related R&D charges. LLY stock is up 8.06%.

Original reporting
Published Oct 29, 2026, 1:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The earnings beat and raised revenue outlook are likely to drive short‑term buying pressure, while the EPS downgrade may introduce volatility.

02

Market read

First‑hand earnings data with new guidance for a large‑cap pharma makes this a high‑value trading story.

03

What to watch

Acquisition‑related R&D charges may recur, and competitive pressure on Mounjaro/Zepbound could temper long‑term growth.

Relevance 9/10Novelty 9/10Timing: after‑hours

Background

Eli Lilly's Q3 2026 earnings release includes detailed segment performance, regulatory approvals, and pipeline updates.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q3 2026 results with 39% revenue growth and raised full-year revenue guidance while cutting adjusted EPS guidance.

Expected impact

mixed direction as market weighs strong top‑line growth against lower earnings guidance

Evidence & confidence

Large‑cap earnings release with new numbers and guidance change; investors will react to both revenue beat and EPS reduction.

Market effects

Boosts outlook for diabetes/obesity therapeutics sector, may lift peers with similar pipelines.

Positive for US biotech and pharma stocks; limited effect on non‑US markets.

Reinforces bullish sentiment for growth‑oriented pharma companies worldwide.

Counterpoint

The EPS cut could signal deeper integration costs, suggesting a short‑term pullback despite revenue growth.

Key entities

  • Eli Lilly and Company

    US‑listed pharmaceutical company reporting Q3 results.

  • Mounjaro

    Lilly's obesity/diabetes drug driving revenue growth.

  • Zepbound

    Lilly's weight‑loss drug contributing to sales.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.